Shareholders filed a class action lawsuit against the company claiming it misrepresented the results of an inconclusive and limited study of its experimental drug AGI-1067. According to the Securities and Exchange Commission, plaintiffs voluntarily dismissed the actions. (Jul-15-05)
[ATLANTA BUSINESS JOURNAL
If you have a similar problem and would like to be contacted by a lawyer at no obligation, please click here to fill in our form
to submit your complaint.